Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T
Hematological Oncology · 2026-03 · 44 (2)
DOI: 10.1002/hon.70183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 03.03.2026. Verfasst von Inna Y Gong und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Princess Margaret Cancer Foundation.
Abstract (Originalsprache)
Bridging therapy (BT) is frequently used in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL) undergoing chimeric antigen receptor T cell (CAR T) therapy, but the optimal BT approach remains uncertain. We evaluated BT strategies and their associations with response and survival outcomes. Accordingly, we included patients with R/R LBCL evaluated for third‐line or later CD19‐directed CAR T at Princess Margaret Cancer Center from 2017 to 2024 (follow‐up to 01/2025). BT modalities included chemotherapy, polatuzumab‐based chemotherapy, radiotherapy, corticosteroids, and none. We assessed the associations of BT modality with overall response rate (ORR), progression‐free survival (PFS), and overall survival (OS) using logistic regression and Cox models. Among 219 patients, 188 underwent apheresis and 157 (84%) received CAR T. Of those apheresed, 79% received BT (radiotherapy 41%, polatuzumab‐based 26%, third‐line chemotherapy 16%, corticosteroids 17%, while 21% received no BT). ORR was highest with polatuzumab (50%) and radiotherapy (40%) versus chemotherapy (16%) ( p = 0.009). Median ΔSUVmax in 84 patients was higher in polatuzumab and radiotherapy treated patients, compared to chemotherapy ( p < 0.001). Radiotherapy encompassing all active disease had higher ORR (51%) versus non‐comprehensive (12%) ( p = 0.04). Two‐year PFS was highest with radiotherapy (47%) and polatuzumab (37%) BT versus chemotherapy (21%). Adjusted analyses showed improved PFS with radiotherapy (adjusted hazard ratio [aHR] 0.29) and polatuzumab (aHR 0.41). OS was also improved with radiotherapy (HR 0.40). Chemotherapy BT was associated with the highest 2‐year lymphoma‐related mortality (74%). In conclusion, polatuzumab‐based and radiotherapy BT as well as no BT were associated with improved responses and outcomes compared to chemotherapy. Although these results may have been influenced by patient selection, prospective studies integrating these approaches are needed to define optimal, individualized BT strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
- Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Princess Margaret Cancer Centre, Radiation Medicine Program, Toronto, Ontario, Canada.
- Princess Margaret Cancer Centre, Biostatistics, Toronto, Ontario, Canada.
- Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
- Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Inna Y Gong, Tomohiro Aoki, Christine Chen, Robert Kridel, Abi Vijenthira
Förderung
- Princess Margaret Cancer Foundation
Zitieren
APA
Gong, I. Y., Jeeva, M., Hueniken, K., Aminilari, M., Marinoni, M., Prica, A., Rodin, D., Bhella, S., Aoki, T., Azab, M., Chen, C., Kridel, R., Kukreti, V., Vijenthira, A., Yang, C., Malik, N., Wells, W., Metser, U., Crump, M., …, & Kuruvilla, J. (2026). Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T. Hematological Oncology, 44(2). https://doi.org/10.1002/hon.70183
Vancouver
Gong IY, Jeeva M, Hueniken K, Aminilari M, Marinoni M, Prica A, et al. Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T. Hematological Oncology. 2026;44(2). doi:10.1002/hon.70183
BibTeX
@article{Gong2026,
author = {Gong, Inna Y and Jeeva, Meenakshi and Hueniken, Katrina and Aminilari, Mahmood and Marinoni, Massimiliano and Prica, Anca and Rodin, Danielle and Bhella, Sita and Aoki, Tomohiro and Azab, Maria and Chen, Christine and Kridel, Robert and Kukreti, Vishal and Vijenthira, Abi and Yang, Chloe and Malik, Nauman and Wells, Woodrow and Metser, Ur and Crump, Michael and Hodgson, David and Kuruvilla, John},
title = {Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T},
journal = {Hematological Oncology},
year = {2026},
volume = {44},
number = {2},
doi = {10.1002/hon.70183}
}
EUVIMED